Skip to content

Combined Ketamine and Propofol in electroconvulsive therapy of depression

Effects of electroconvulsive therapy using ketamine and propofol as anesthetic agent on the improvement of depression in patients with major depressive disorder

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT138811022935N2
Enrollment
50
Registered
2010-09-11
Start date
2010-10-02
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder. recurrent depressive disorder

Interventions

Intervention 1: ketamine (0.3mg/kg) plus Atropine 0.5 mg (study) for induction of anesthesia before injection of Propofol. Intervention 2: Saline plus Atropine 0.5 mg for induction of anesthesia befor
Treatment - Drugs
Placebo
ketamine (0.3mg/kg) plus Atropine 0.5 mg (study) for induction of anesthesia before injection of Propofol

Sponsors

Kurdistan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis by Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 2000), of major depressive disorder, age between 18 to 40 years old, Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 13, IQ>70 Exclusion criteria: drug or alcohol dependence, any contraindication of ECT, depressive disorder with psychotic features, history of epilepsy, ASA class >2, history of cognitive disorder

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Severity of depression. Timepoint: baseline and one day after the third and the last ECT session and 2 weeks after the last session. Method of measurement: Hamiltion Depression Rating Scale 17-Item.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farzin Rezaei

Kurdistan University of Medical Sciences

farrezaei@muk.ac.ir; Farzin.Rezaie@uok.ac.ir ; frrezaie@yahoo.com+98 87 1356 1822

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026